Clinuvel Share Price
NASDAQ: CUVL | OthersClinuvel Stock Performance
Clinuvel Share Price Chart
Corporate Actions
About Clinuvel
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Clinuvel Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $4.96 | $4.86 | -8.40% |
Oct 2026 | $5.20 | $5.30 | -5.36% |
Sep 2026 | $6.06 | $5.60 | -20.06% |
Aug 2026 | $6.41 | $7.00 | +0.07% |
Jul 2026 | $7.80 | $7.00 | N/A |